Research Article
Geriatric Nutritional Risk Index Predicts Adverse Outcomes in Human Malignancy: A Meta-Analysis
Table 1
Summary characteristics of included studies in this meta-analysis.
| | Author information | Year | Country | Cancer species | No. of patients | Age | Gender ratio | Primary therapy | Cut-off for GNRI (no-risk/risk) | Endpoint | HR and 95% CI | Source of HR | Analytic method | Follow-up interval (months) |
| | Konishi et al. [15] | 2019 | Japan | Acute myeloid leukemia | 63 | >50 | 21/42 | Stem cell transplantation | 98 (31/32) | OS, DFS | OS HR: 2.30 (1.19-4.46) | Data | Univariate | Median 33.9 (0.6-68.1) | | | | | | | | | | | DFS HR: 2.18 (1.11-4.26) | Data | Univariate | | | Mizuno et al. [16] | 2019 | Japan | Follicular lymphoma | 130 | Median 67 (32-91) | 70/60 | Chemotherapy | 99.2 (96/34) | OS | OS HR: 5.65 (2.66-12.00) | Data | Univariate | Median 52 | | Li et al. [17] | 2018 | China | DLBCL | 267 | NR | 121/156 | Chemotherapy | 98 (162/105) | OS | OS HR: 0.81 (0.44-1.48) | Crude | Multivariate | Up to 72 | | Kanemasa et al. [18] | 2018 | Japan | DLBCL | 476 | Median 68 (27-97) | 210/266 | Chemotherapy | 96.8 (221/255) | OS, PFS | OS HR: 2.05 (1.31-3.22) | Crude | Multivariate | Median 45 | | | | | | | | | | | PFS HR: 1.93 (1.47-2.53) | Data | Univariate | | | Yang et al. [19] | 2018 | China | DLBCL | 249 | Median 60 (18-85) | 107/142 | Chemotherapy | 96.6 (136/113) | OS, PFS | OS HR: 1.28 (0.79-2.06) | Crude | Multivariate | Median 16 (0-51) | | | | | | | | | | | PFS HR: 1.46 (1.11-1.91) | Data | Univariate | | | Yamana et al. [20] | 2018 | Japan | ESCC | 216 | NR | NR | Resection | 92 (153/63) | OS | OS HR: 2.44 (1.59-3.70) | Crude | Univariate | Up to 60 | | Kubo N [21] | 2018 | Japan | EC | 240 | Mean 63.3 (66-113) | 44/196 | Resection | 92(196/44) | OS, CSS | OS HR: 1.69 (1.04-2.74) | Crude | Multivariate | Up to 60 | | | | | | | | | | | CSS HR: 1.60 (0.91-2.82) | Crude | Multivariate | | | Migita et al. [22] | 2018 | Japan | ESCC | 137 | NR | 21/116 | Resection | 98 (92/45) | OS, DFS | OS HR: 2.10 (1.18-3.72) | Crude | Multivariate | Up to 60 | | | | | | | | | | | DFS HR: 1.23 (1.00-1.51) | Data | Univariate | | | Bo et al. [23] | 2016 | China | ESCC | 239 | Mean 67.9 (60-88) | 89/150 | Radiotherapy | 98 (184/55) | OS | OS HR: 1.69 (1.02-2.80) sub1 | Crude | Multivariate | Up to 60 | | | | | | | | | | | OS HR: 2.70 (1.51-4.82) sub2 | Crude | Multivariate | | | Li et al. [24] | 2018 | China | Hepatocellular carcinoma | 261 | Median 68 (67-70) | 46/215 | Resection | 98 (197/64) | OS, DFS | OS HR: 1.05 (0.97-1.14) | Data | Univariate | Up to 60 | | | | | | | | | | | DFS HR: 1.29 (1.06-1.57) | Data | Univariate | | | Hu et al. [25] | 2019 | China | Pancreatic cancer | 265 | NR | 109/156 | Resection | 98 (170/95) | OS | OS HR: 1.54 (1.12-2.12) | Crude | Multivariate | Up to 60 | | Miyake et al. [26] | 2017 | Japan | Renal cell carcinoma | 432 | NR | 155/277 | Resection | 98 (325/107) | CSS, DFS | CSS HR: 3.37 (1.86-6.14) | Data | Univariate | Up to 100 | | | | | | | | | | | DFS HR: 1.52 (1.04-2.22) | Data | Univariate | | | Kang et al. [27] | 2019 | Korea | Renal cell carcinoma | 4591 | NR | 1224/3367 | Resection | 98 (3859/732) | CSS, DFS | CSS HR: 1.67 (1.19-2.34) sub1 | Crude | Multivariate | Median 37 (18-68) | | | | | | | | | | | CSS HR: 1.61 (1.13-2.28) sub2 | Crude | Multivariate | | | | | | | | | | | | DFS HR: 1.33 (0.82-2.17) sub1 | Crude | Multivariate | | | | | | | | | | | | DFS HR: 3.18 (2.00-5.06) sub2 | Crude | Multivariate | | | Okamoto et al. [28] | 2018 | Japan | Prostate cancer | 339 | Median 72 | 0/339 | Androgen-deprivation | 92 (273/66) | OS, CSS | OS HR: 1.80 (1.13-2.87) | Crude | Multivariate | Median 26 (12-53) | | | | | | | | | | | CSS HR: 1.76 (1.04-2.98) | Crude | Multivariate | | | Shoji et al. [29] | 2017 | Japan | Lung cancer | 141 | Median 68 (37-86) | 80/61 | Resection | 98 (119/22) | OS, CSS, DFS | OS HR: 4.58 (2.36-8.87) | Data | Univariate | Median 58 (0-94) | | | | | | | | | | | CSS HR: 3.09 (0.98-9.68) | Data | Univariate | | | | | | | | | | | | DFS HR: 4.03 (1.45-10.73) | Crude | Multivariate | |
|
|
Abbreviations: DLBCL: diffuse large B cell lymphoma; NR: no reported; ESCC: esophageal squamous cell carcinoma; EC: esophageal cancer; OS: overall survival; CSS: cancer-specific survival; DFS: disease-free survival; PFS: progression-free survival; HR: hazard ratio.
|
